Inci Alacacioglu
Overview
Explore the profile of Inci Alacacioglu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Erdogan Yucel E, Kirmaz A, Kakci M, Yavuz A, Sencelikel T, Alacacioglu I, et al.
J Clin Med
. 2024 Jul;
13(14).
PMID: 39064182
This retrospective one-center study demonstrates the complications related to high-dose therapy with autologous stem cell support (HDT) and the survival of multiple myeloma (MM) patients according to age groups. :...
2.
Arat M, Alacacioglu I, Bolaman A, Buyukasik Y, Cagirgan S, Guvenc B, et al.
Future Oncol
. 2023 Jun;
19(14):975-982.
PMID: 37293766
To determine the unmet needs and challenges in management, diagnosis, treatment, follow-up and patient-physician communication in acute leukemia (AL). The study was based on a modified Delphi approach. A questionnaire...
3.
Birtas Atesoglu E, Gulbas Z, Uzay A, Ozcan M, Ozkalemkas F, Dal M, et al.
Hematol Oncol
. 2023 May;
41(4):663-673.
PMID: 37211991
Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal...
4.
Esmeray Sonmez E, Hatipoglu T, Kursun D, Hu X, Akman B, Yuan H, et al.
Cells
. 2022 Nov;
11(21).
PMID: 36359790
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL) subtype characterized by overexpression of CCND1 and SOX11 genes. It is generally associated with clinically poor outcomes despite recent...
5.
Solmaz S, Uzun O, Sevindik O, Demirkan F, Ozcan M, Ozsan G, et al.
Int J Lab Hematol
. 2022 Sep;
45(1):13-19.
PMID: 36053932
Introduction: In multiple myeloma cases, a variety of prognostic parameters have been identified, which contain the Durie-Salmon classification and the international staging system (ISS) that takes the serum ß2 microglobulin...
6.
Hatipoglu T, Esmeray Sonmez E, Hu X, Yuan H, Danyeli A, Seyhanli A, et al.
Front Oncol
. 2022 Jul;
12:870487.
PMID: 35795062
Follicular lymphoma (FL) is the second most frequent non-Hodgkin lymphoma accounting for 10-20% of all lymphomas in western countries. As a clinically heterogeneous cancer, FL occasionally undergoes histological transformation to...
7.
Seyhanli A, Yavuz B, Aksit Z, Yuce Z, Ozkal S, Altungoz O, et al.
Turk J Haematol
. 2021 Nov;
39(2):109-116.
PMID: 34823323
Objective: Multiple myeloma (MM) is a malignant condition characterized by the accumulation of malignant plasma cells. Although MM remains incurable, the survival of MM patients has improved considerably due to...
8.
Seyhanli A, Ozkan Y, Bengi G, Alacacioglu I, Ozsan G, Demirkan F
Transfus Apher Sci
. 2021 Aug;
60(6):103247.
PMID: 34462217
Aim: Management of blood transfusions is a critical issue, especially in cirrhotic patients, because of the absence of national policies in many countries. Fresh frozen plasma (FFP) is a common...
9.
Seyhanli A, Yavuz B, Selimoglu I, Sengun I, Aslan A, Ozsan G, et al.
Ther Apher Dial
. 2021 Jun;
26(2):465-470.
PMID: 34173719
Therapeutic plasma exchange (TPE) is an apheresis procedure in which plasma is separated from the blood cellular components ex vivo, allocated, and replaced with another plasma or a plasma-replacing fluid....
10.
Gemici A, Ozkalemkas F, Dogu M, Tekinalp A, Alacacioglu I, Guney T, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Jun;
21(8):e686-e692.
PMID: 34059487
Introduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in...